Bovine respiratory syncytial virus protects cotton rats against human respiratory syncytial virus infection
| Autor: | V. G. Hemming, F. M. Piazza, D. D. Porter, G. A. Prince, M. E. R. Darnell, S. A. Johnson |
|---|---|
| Rok vydání: | 1993 |
| Předmět: |
Paramyxoviridae
Immunology Cross Reactions Antibodies Viral Virus Replication Microbiology Respirovirus Infections Virus Species Specificity Immunity Virology Animals Cotton rat Sigmodontinae Neutralizing antibody Antigens Viral Administration Intranasal biology Viral Vaccine Immunotherapy Active Viral Vaccines biology.organism_classification Respiratory Syncytial Viruses Titer Immunity Active Evaluation Studies as Topic Insect Science biology.protein Viral disease Research Article |
| Zdroj: | Journal of virology. 67(3) |
| ISSN: | 0022-538X |
| Popis: | Human respiratory syncytial virus (HRSV) is the most frequent cause of severe respiratory infections in infancy. No vaccine against this virus has yet been protective, and antiviral drugs have been of limited utility. Using the cotton rat model of HRSV infection, we examined bovine respiratory syncytial virus (BRSV), a cause of acute respiratory disease in young cattle, as a possible vaccine candidate to protect children against HRSV infection. Cotton rats were primed intranasally with graded doses of BRSV/375 or HRSV/Long or were left unprimed. Three weeks later, they were challenged intranasally with either BRSV/375, HRSV/Long (subgroup A), or HRSV/18537 (subgroup B). At intervals postchallenge, animals were sacrificed for virus titration and histologic evaluation. Serum neutralizing antibody titers were determined at the time of viral challenge. BRSV/375 replicated to low titers in nasal tissues and lungs. Priming with 10(5) PFU of BRSV/375 effected a 500- to 1,000-fold reduction in peak nasal HRSV titer and a greater than 1,000-fold reduction in peak pulmonary HRSV titer upon challenge with HRSV/Long or HRSV/18537. In contrast to priming with HRSV, priming with BRSV did not induce substantial levels of neutralizing antibody against HRSV and was associated with a delayed onset of clearance of HRSV upon challenge. Priming with BRSV/375 caused mild nasal and pulmonary pathology and did not cause exacerbation of disease upon challenge with HRSV/Long. Our findings suggest that BRSV may be a potential vaccine against HRSV and a useful tool for studying the mechanisms of immunity to HRSV. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|